ATLANTA, Feb. 2 /CNW/ -- AtheroGenics, Inc.
(Nasdaq: AGIX), a pharmaceutical company focused on the treatment of chronic
inflammatory diseases, today announced an extension of its research and
development collaboration with Astellas Pharma Inc. for AGI-1096, an
AtheroGenics oral drug candidate being evaluated for the prevention of chronic
organ transplant rejection.
